CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionPrice-to-book is 138.64×, higher than 95% of its Biotechnology peers (median 2.97×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
449.38MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6220xvs all stocks
52-Week Change
-9.71%vs all stocks
Market Capitalization
449.38MUSDvs all stocks (USD)
Enterprise Value
678.64MUSDvs all stocks (USD)
Forward P/E
-3.08xvs Biotechnology peers
Price to Book (MRQ)
138.64xvs Biotechnology peers
Enterprise to EBITDA
-6.69xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-41.35%vs Biotechnology peers
Return on Equity (TTM)
-74.60%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-101.47MUSDvs all stocks (USD)
Net Income (TTM)
-105.41MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-94.92MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-58.82MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2026 · Mar 31, 2026Operating Income
-142.59MUSDvs all stocks (USD)
Pre-tax Income
-148.00MUSDFY2026 · Mar 31, 2026Net Income
-148.00MUSDFY2026 · Mar 31, 2026EBIT
-142.59MUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
-137.46MUSDFY2026 · Mar 31, 2026Research & Development
86.59MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
56.00MUSDFY2026 · Mar 31, 2026Non-operating Interest Income
5.10MUSDFY2026 · Mar 31, 2026Net Income from Continuing Operations
-148.00MUSDFY2026 · Mar 31, 2026Operating Cash Flow
-135.93MUSDFY2026 · Mar 31, 2026Free Cash Flow
-137.29MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
157.26MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-148.00MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
120.00KUSDFY2026 · Mar 31, 2026Stock-based Compensation
10.86MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-934.00KUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
2.02MUSDFY2026 · Mar 31, 2026Capital Expenditures
-1.36MUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
-1.36MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-20.15MUSDFY2026 · Mar 31, 2026Net Short-term Debt Issuance
24.35MUSDFY2026 · Mar 31, 2026Other Financing Charges
-315.00KUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
149.94MUSDFY2026 · Mar 31, 2026Shares Outstanding
51.63MSharesUpdated Jul 19, 2026Shares Short
3.11MSharesUpdated Jul 19, 2026Short Ratio
2.42daysvs all stocks
% Held by Insiders
2.75%vs all stocks
% Held by Institutions
39.86%vs all stocks
Total Cash (MRQ)
146.98KUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0020USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
9.52xvs Biotechnology peers
Book Value per Share (MRQ)
0.0523USDUpdated Jul 19, 2026Total Assets
354.58MUSDvs all stocks (USD)
Total Current Assets
260.50MUSDFY2026 · Mar 31, 2026Total Liabilities
27.36MUSDFY2026 · Mar 31, 2026Total Non-current Assets
94.08MUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
0.00USDFY2026 · Mar 31, 2026Total Current Liabilities
27.36MUSDFY2026 · Mar 31, 2026Cash
222.01MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
222.01MUSDFY2026 · Mar 31, 2026Accounts Receivable
7.10MUSDFY2026 · Mar 31, 2026Common Stock (Book)
694.72MUSDFY2026 · Mar 31, 2026Retained Earnings
-549.92MUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
327.22MUSDvs all stocks (USD)
52-Week Low
3.76USDUpdated Jul 19, 202652-Week High
9.12USDUpdated Jul 19, 202652-Week Change
-9.71%vs all stocks
Beta
0.6220xvs all stocks
50-Day MA
5.21USDUpdated Jul 19, 2026200-Day MA
6.00USDUpdated Jul 19, 2026Avg 10-Day Volume
1.66MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.42MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.25USDUpdated Jul 19, 2026Other Income / Expense
-7.59MUSDFY2026 · Mar 31, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 138.64×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 138.644Industry median: 2.97Industry P95: 23.50Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Altman Z-Score 7.15: safe zoneNotable
Altman Z-Score: 7.15
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule